RxDoctor Payments Data

Eric Huerter, MD

Internal Medicine · Lawrence, KSNPI 1225133812

Payments from drug & device makers

$2,085in general payments, 2019–2025

Across 115 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$424
  • GSK$315
  • Amgen$161
  • Pfizer$94
  • Boehringer Ingelheim$85
  • Novo Nordisk$79
  • plus $926 from 30 others

What the payments were for

  • Food & beverage$2,07099%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,085 in reported general payments places this provider in the 80th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$326,212
Medicare patients
528
Services billed
12,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban431$197,236
JardianceEmpagliflozin135$92,444
XareltoRivaroxaban139$82,918
VascepaIcosapent Ethyl153$52,616
OzempicSemaglutide57$51,586
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$33,104
Xtampza ErOxycodone Myristate26$32,357
JanuviaSitagliptin Phosphate84$31,946
LinzessLinaclotide48$26,890
ArexvyRsvpref3 Antigen/As01e/Pf74$23,976
CreonLipase/Protease/Amylase31$19,264
Repatha SureclickEvolocumab24$16,523
EntrestoSacubitril/Valsartan28$15,268
TrulicityDulaglutide11$14,503
FarxigaDapagliflozin Propanediol16$14,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Dilantin$94$212,617490 claims
Boehringer IngelheimJardiance, Tradjenta$85$98,574147 claims
Johnson & JohnsonXarelto$20$82,918139 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix$315$79,719196 claims
Novo NordiskOzempic$79$51,58657 claims
MerckJanuvia$37$31,94684 claims
NovartisEntresto$424$15,26828 claims
Lilly USA, LLCTrulicity$69$14,50311 claims
AstraZenecaFarxiga$44$14,14716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Lawrence

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →